Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma

Trial Details

NCT ID

NCT05348213

Phase

PHASE2

Sponsor

Ruijin Hospital

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• Zanubrutinib plus R-ICE
• Decitabine plus R-ICE
• Chidamide plus R-ICE
• Tofacitinib plus R-ICE
• Pomalidomide plus R-ICE

Locations (sample)

• Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

• DLBCL was confirmed by histology according to world Health Organization (WHO) disease classification (excluding primary central lymphoma and HIV-as…
• There are evaluable lesions detected by PET/CT;
• Life expectancy of more than 3 months;
• Prior treatment with sufficient first-line anti-lymphoma therapy, no remission within 90 days of the last administration, or disease progression af…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.